Luminescent platinum(II) complexes with biazolate chelates

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The National Tsing Hua University patent solves the following problem:

This invention relates to a platinum complex for an organic light-emitting diode, especially a phosphorescent platinum complex with a dianionic bidentate ligand and a bidentate nitrogen-containing heteroaromatic ligand.

Our analysis of this patent is as follows:

National Tsing Hua University’s patent US 9040702 B1 deals with Luminescent platinum(II) complexes with biazolate chelates.
A platinum complex of formula (I): wherein R1 and R2 are each fluoroalkyl, X is CH or nitrogen, and L1 is a bidentate, nitrogen-containing heteroaromatic ligand.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibody-nanoparticle conjugates and methods for making and using such conjugates

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ventana Medical Systems, Inc. patent solves the following problem:

Immunohistochemistry (IHC) using a specific value agents, such as antibodies, in recognition of an antigen of interest to be present in a tissue sample. IHC is widely used in clinical and diagnostic applications, such as the diagnosis of certain disease states or conditions. For example, a particular type of cancer can be diagnosed based on the presence of a particular marker molecules in a sample obtained from a subject. IHC is also widely used in basic research to understand the biomarker distribution and localization in different parts of tissue.

Our analysis of this patent is as follows:

Ventana Medical Systems, Inc.’s patent US 9040310 B2 deals with Antibody-nanoparticle conjugates and methods for making and using such conjugates.
Is disclosed in the antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, Palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly involved an antibody or fragment thereof by a metal-thiol bond. Methods of making antibody-nanoparticle conjugates disclosed here includes a reaction arylphosphine-nanoparticle composite with a reduced antibody to generate an antibody-nanoparticle conjugate. Also disclosed here are methods of identifying a target molecule in a sample that includes the use of an antibody-nanoparticle conjugate (such as antibody-nanoparticle conjugates described it) and kits for identifying target molecules using expresses here.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Phenoxyisobutyric acid compounds and method of synthesis

File for Quick & Easy Patent Protection with PowerPatent.

The Cell Viable Corporation patent solves the following problem:

The present invention relates in general synthesis and production of novel substituted arylureidophenoxymethylpropionic acids useful in pharmaceutical applications. One use of the disclosed compounds as anti AGE (Advanced Glycation Products) compound for the treatment of diabetes.

Our analysis of this patent is as follows:

Cell Viable Corporation’s patent US 9040553 B2 deals with Phenoxyisobutyric acid compounds and method of synthesis.
The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of years (Advanced Glycation End Products).

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

2,4-pyrimidinediamine compounds and their uses

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Rigel Pharmaceuticals, Inc. patent solves the following problem:

Crosslinking the Fc receptor, such as the high affinity receptor for IgE (FCRI) and / or the high affinity receptor for IgG (FCRI) activates a signaling cascade in mast, basophil and other immune cells that results in release of chemical mediators responsible for many negative events. For example, such crosslinking leads to the release of preformed mediators of Type I (immediate) anaphylactic hypersensitivity reactions, such as histamine, from the treasury of granules by degranulation. It also led to the synthesis and release of other teachers, including leukotrienes, prostaglandins and platelet-activating factor (PAF), which play important roles in inflammatory reactions. Additional mediator that artificially and released crosslinking Fc receptors include cytokines and nitric oxide.

Our analysis of this patent is as follows:

Rigel Pharmaceuticals, Inc.’s patent US 9040550 B2 deals with 2,4-pyrimidinediamine compounds and their uses.
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and / or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of use compounds in a variety of contexts, including the treatment and prevention of diseases characterized by, for or associated with the release of chemical mediators in degranulation and other processes performed by the activation of IgE and / or IgG receptor signaling cascades.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Reduction of ALMS1 gene expression or inhibition of altrm protein to induce cardiomyocyte proliferation

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The Johns Hopkins University patent solves the following problem:

Mammal heart development requires continued proliferation of cardiomyocytes throughout pregnancy (1, 2). During the perinatal period, cardiomyocyte proliferation rapid decline, and most of the cardiomyocytes undergo cell cycle arrest in terminal differential (3, 4). Postnatal arrest cardiomyocyte cell cycle is a key event for the maturation of the mammal heart, but this process is poorly understood (3).

Our analysis of this patent is as follows:

The Johns Hopkins University’s patent US 9040496 B2 deals with Reduction of ALMS1 gene expression or inhibition of altrm protein to induce cardiomyocyte proliferation.
The present invention relates to the field of heart. More particularly, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. At a certain image, a method for inducing proliferation of cardiomyocytes comprising the step of administering an effective amount of a ALMS1 inhibitor.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Treatment and diagnosis of colon cancer

File for Quick & Easy Patent Protection with PowerPatent.

The The Rockefeller University patent solves the following problem:

Colon cancer, commonly known as colorectal cancer or bowel cancer, is a cancer of uncontrolled cell growth in the colon or rectum, or in the appendix. See for example, Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer, Nature 487: 330-337 (19 May 2012). It is the second most frequently diagnosed cancer in the United States and the second most common cause of cancer death. For example, the five-year survival rate for patients with colorectal cancer detected in an early localized stage is 92%, while the survival rate drops to 64% if the cancer is allowed to spread to neighboring organs or lymph nodes, and in 7% of patients with distant metastases.

Our analysis of this patent is as follows:

The Rockefeller University’s patent US 9040497 B2 deals with Treatment and diagnosis of colon cancer.
The present invention discloses novel agents and methods for the diagnosis and treatment of breast cancer, colon cancer. Also said that relevant arrays, kit, and screening procedures.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Kymab Limited patent solves the following problem:

It is recognized that every race people in their ranks and to just a few individuals in their genomes sequenced, for example, James Watson and Craig Venter. Comparing the genome of the man revealed a difference in their ranks in both coding and non-coding parts of the genome. With these differences in people are important and contribute to phenotypic differences between individuals. In extreme cases this can lead to genetic disease. The 1000 Genomes Project aims sorting sequences in the human genome, which includes a series of genomes in a very large sample of people from different art-recognized human ethnic population.

Our analysis of this patent is as follows:

Kymab Limited’s patent US 9040052 B1 deals with Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment.
The invention relates to human target interest (toi), anti-toi ligands, kits compositions and methods.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods and device to neutralize soluble toxic agents in the brain

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Medtronic, Inc. patent solves the following problem:

Various methods aimed at the treatment of diseases caused or showed enhanced secretion of an otherwise normal protein, production of a pathological soluble or membrane bound proteins, or abnormal conformational changes or folding a a peptide or protein in a mammal. Traditional techniques to target the toxic protein or aberrant expression of proteins involved in the administration of small molecules that affect the rate or amount of production of the protein or antibody that specifically binds to the protein of interest and cause them to be cleared from the body.

Our analysis of this patent is as follows:

Medtronic, Inc.’s patent US 9040045 B2 deals with Methods and device to neutralize soluble toxic agents in the brain.
Methods, agents and devices for the treatment of a patient to reduce the accumulation of certain proteins in the brain described. Such proteins include one, and the methods, agents and devices useful for reducing the accumulation of one, which is a principal constituent of the plaques associated with the disease such as pain Alzheimer's disease (AD). Antibody to one, when delivered systemically or directly into the central nervous system, improving the thinking deficits in a transgenic mouse model of AD. But, unlike the peripheral of antibody to some, the increased cerebral vascular plaque and bleeding, direct central administration did not result in such an increase in brain vascular plaque and bleeding.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

ADAM-15 antibodies and immunogenic peptides

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Vasgen Limited patent solves the following problem:

Cancer is one of the biggest killers in the world, with approximately 7.6 million people died of cancer in 2005representing 13% of deaths worldwide. Between 2005 and 2015, 84 million more people will die if urgent action is not (WHO forecast). Such statistics have prompted a largescale investment in cancer research in both the public and private health sectors. Therefore, there is an urgent need to translate medical research into the development of new cancer treatments and drugs.

Our analysis of this patent is as follows:

Vasgen Limited’s patent US 9040049 B2 deals with ADAM-15 antibodies and immunogenic peptides.
The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide (s), and siRNA molecules capable of inhibiting neovascularization and / or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity to the metalloprotease domain of ADAM 15 and immunogenic peptide (s) that make these antibodies. invention also relates to compositions and kits comprising the antibodies and immunogenic peptide (s) to produce, as well as procedures and using the antibody and antigen-binding fragments thereof, and immunogenic peptide (s), as well as siRNA molecules.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

HLA-restricted, peptide-specific antigen binding proteins

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Memorial Sloan Kettering Cancer Center patent solves the following problem:

The present invention relates generally to the antigen-binding protein molecules involved in immune function. Particularly, the present invention relates to artificial antibody, chimeric antigen receptor and its fragments with specificity for a hľa-restricted peptide, wherein the peptide is derived from a cellular or viral proteins of interest.

Our analysis of this patent is as follows:

Memorial Sloan Kettering Cancer Center’s patent US 9040669 B2 deals with HLA-restricted, peptide-specific antigen binding proteins.
Antigen binding proteins in T cell receptor-like paratopes, that is, with an antigen binding region specific for a human leukocyte antigen-A2 restricted peptide expressed. The antigen binding protein antibody encompass a variety of forms, including full-length antibody, substantially intact antibody, Fab fragments, F (a) 2 fragments, and single chain Fv particle. Fusion proteins, such as scFv substitutes immunoglobulin or T-cell receptor domains, using the specificity of antigen binding regions for each peptide also contemplates the creation. Further, immunoconjugates may include antibody to be linked to a radioisotope, fluorescent or other detectable label, cytotoxin, or other molecules that surrounded the building. Among other things, immunoconjugates can be used for the delivery of an agent to obtain a therapeutic effect or facilitate an immune effector function.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.